Osteoporosis Study Validates CompuMed's OsteoGram(R) Screening Technology

Main Category: Bones / Orthopaedics
Also Included In: Medical Devices / Diagnostics
Article Date: 30 Oct 2008 - 9:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

A large scale study led by renowned osteoporosis researcher Dr. Jianhua Wang and presented at the recent 6th International Conference on Bone and Mineral Research in Hohhot, China affirms the precision and accuracy of CompuMed Inc.'s OsteoGram® system for low cost osteoporosis screening.

Dr. Wang's presentation titled "Study on Measurement of Phalangeal Bone Density by Radiographic Absorptiometry" presented extremely precise results when performing short-term repeated tests with CompuMed's OsteoGram® system. In addition, the study outcome was highly correlated to China's popular osteoporosis normal database, confirming the high accuracy of OsteoGram. Radiographic absorptiometry (RA) is a technique for bone mass measurement from radiographs of peripheral sites, most commonly the hand or heel.

"This was one of the largest and most thorough studies ever performed to study the value of RA in measuring bone mineral density," said CompuMed CEO Maurizio Vecchione. "The results further affirm that the OsteoGram is an effective and efficient alternative to costly DXA systems."

The OsteoGram is a software-based bone density measurement system that can be used with digital x-ray equipment, as well as with older film-based machines. It provides a low-cost alternative to DXA bone mineral density (BMD) screening systems, which require dedicated and costly equipment, office space and staff. The OsteoGram's benefits in terms of cost and efficiency can help facilitate more widespread osteoporosis screening and treatment of at-risk patients.

Last July, CompuMed announced that the company had received approval from China's State Food and Drug Administration (SFDA) to sell the OsteoGram system and therefore work with Chinese OEMs to penetrate one of the world's largest and fastest growing markets for osteoporosis screening. The disease is especially prevalent in China, where the traditional diet lacks the calcium required to build strong bones. More than 125 million postmenopausal women are at risk for osteoporosis in China, with an estimated 100 million-plus already suffering from the disease in various stages.

About CompuMed

CompuMed, Inc. (OTCBB:CMPD) develops and markets products and services that combine advanced imaging with medical informatics. Its focus is on analysis and remote monitoring for patients with cardiovascular and musculoskeletal diseases. The Company has specialized expertise and intellectual property in telemonitoring imaging and analysis designed to improve healthcare provider workflow and patient care while reducing costs. CompuMed's core products, the OsteoGram® and CardioGram™, are cleared by the FDA and reimbursable by Medicare. The OsteoGram is a non-invasive diagnostic system that has been proven by many clinical studies to provide effective and accurate bone density measurement for screening osteoporosis and assessing hip fracture risk. The OsteoGram has significant cost advantages over other technologies in the marketplace. The CardioGram system is one of the first telecommunication networks designed to remotely interpret electrocardiograms and is used by private practice, as well as government and corporate healthcare providers nationwide. The CardioGram delivers online electrocardiogram interpretations within minutes of receipt and has the additional capability of automatically providing an over-read (i.e., follow-up review) by a cardiologist. CompuMed is headquartered in Los Angeles and distributes its products worldwide both directly and through OEM partners. Visit CompuMed on-line at http://www.compumed.net.

Statements contained in this press release that are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth, results of contracts and other financial results, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including statements concerning the Company's plans, objectives, expectations and intentions are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These statements are subject to uncertainties and risks including, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, product and service demand and acceptance, changes in technology, ability to raise capital, the availability of appropriate acquisition candidates and/or business partnerships, economic conditions, the impact of competition and pricing, capacity and supply constraints or difficulties, government regulation and other risks identified in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-KSB and Quarterly Reports on Form 10-QSB. All such forward-looking statements are expressly qualified by these cautionary statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect events, conditions or circumstances on which any such statement is based after the date hereof, except as required by law.

Source
Susan M. Tellem
Tellem Worldwide, Inc.

CompuMed Inc.